Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

Humira®, manufactured by AbbVie, is again at the top of the list and semaglutide (Ozempic® and Wegovy ... construction (4.9%), water services (5.1%) and medical gases (4%). Pharmacy projections ...

Novo Nordisk shares surged on the results of a new obesity-drug study Friday. The Danish pharmaceutical giant behind Ozempic ...

The pharmacy benefit manager ... indication to Wegovy in March 2024. A peer-reviewed study published this past autumn estimated that about 4.7 million U.S. adults would meet SELECT trial ...

Of the hundreds of drugs that entered the U.S. market in 2024 ... It will be available for the 2025-26 flu season. 4. Neffy (epinephrine): The first non-injectable form of the drug approved ...

and medical gases (4%). Pharmacy projections are based on Vizient client purchases from Oct. 1, 2023, through Sept. 30, 2024. Non-pharmacy supply chain projections are based on a Vizient analysis of ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

To corral costs, Keith is leading a new initiative at BCBSM called Blue Cross Accelerated that aims to cut $600 million in administrative costs.

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

Wegovy sells for a list price — or price before discounts — of $1,349 per month in the U.S. The same drug lists for $265 in Canada and less than half of that in the U.K. These dramatic differences ...

But doctors specializing in weight loss say that microdosing these drugs – which include compounded versions of types of GLP-1 medications, including Ozempic and Wegovy – hasn’t been studied ...